As a part of the collaboration between Lema'anchem organization, Weizmann institute of science and the University of Ariel a team from the organization gathered for a talk with Prof. Cyrille Cohen, tenured professor at the University of Bar-Ilan, and Immunologist that specializes in the immune system with a specialty in the field of genetic engineering of the human immune system. Prof. Cohen Is a member of a few committees in the Israeli ministry of health including the consulting committee to clinical trials and advanced therapies that among other things criticizes the COVID-19 vaccine. Now that Prof. Cohen has joined the 'Reserve physicians' of the Lema'anchem orgonizatin he will contribute his share in the fields of cancer research and genetic engineering of the immune system. In the conversation were present chairman of the organization, Rabbi Yossi Erblich, the president of the organization Prof. Yosef Peres, the manager of the professional field Dr. Benny Davidzon, the organization head rabbi, Zvi Lao.a team of medical consulters and a part of the doctors in the 'Reserve physicians'.
The corona vaccinations given in the Israeli vaccination operation are based on the mRNA technology that begin her way in the field of cancer research. As known this vaccinations went through the strictest tests and had received the approval of the FDA, and studies have showed that two doses of the vaccine provides an efficiency of 93%.

Nevertheless, Prof. Cohen discusses two risks that should be considered about theCOVID-19 vaccine operation; the first is relevant to most of the vaccines today and not only for covid vaccines and is the state where the antibodies that are made by the vaccines are not good enough and might in the encounter with virus or the variant increase the illness. It's important to clarify that up until now there hasn’t been spotted any cases of this case, even after tens of millions has Been vaccinated and many of them had probably met the virus after the full vaccination.

The other risk refers to the topic of autoimmune diseases, and the chance if an unwanted response developed by the vaccine. This kind of response can damage healthy cells. In this case as well, with all the precautions, it's safe to say that immunological a response like that has yet to be seen. Furthermore, true to this date, a year after the the outbreak, we still don't know all the side effects of the covid-19 virus.

Prof. Cohen also addressed more approaches to developing covid vaccines that might increase the level of antibodies in the human body. The known approaches are the inactive virus vaccine and the attenuated vaccine. As for the inactive virus vaccine, the difficulty is creating vast infrastructure in which the virus is grown in a large countety.as for now this infrastructure is not vastly available and is available only in India and China. As for the attenuated vaccine, it is successfully used against the flu virus, but not in addressing the COVID-19 virus, we are still lacking the right technology. Furthermore, the attenuated vaccine suffers from a negative image because of the misconception that the vaccine inserts the body a form of a weak disease, a fact that is incorrect. That leave us with less known vaccines, including the vectors like the vaccinations a "JHONSON and JHONSO" and "ASTRAZENICA" and the vaccine of the "Biologic institute" in Nes Ziona.

This vaccines can may provide complementary protection to the mRNA vaccines and contribute to the strengthening of the immune memory but because there were no vast testing done on this vaccines there is no way of predicting what will be their donation to the antibody level and as for this moment it is unknown territory.
As stated, the mRNA technology arrived from cancer research in order to create a vaccine that can correct genetic flaws by transferring "recipe" to making proteins that are missing in the body. But yet, although in the case of a virus, the vaccine teaches to body to identify a foreign matter, in case of cancer it is much more complicated because the cancer cells are developing internally from within the body and the bod recognizes it as self-material.
Lema'anchem orgonizatin sees in this research field a top priority and therefore offered Prof. Cohen its help in gathering test subject's in order to help develop immunologic drugs and also offered the help of the organization doctors which are in 'reserve physicians' that will help him with anything he might need. Prof. Cohen on his behalf, invited the members of Lema'anchem orgonizatin for a visit in the labs of the University of Bar Ilan in order to present the newest technologies in immunotherapy cancer treatment.

In conclusion, Rabbi Erblich thanked Prof. Cohen for his willingness to help the community and helping the Lema'anchem organization, an organization that is committed to three things: professionalism, service and innovation. The Rabbi of the organization. Rabbi Tsvi Lao, blessed Prof. Cohen in a liturgical poem, sang in the prayer prayed in the Yom hakipurim: "As the candle that shines in the windows was the appearance of the Cohen' (From Yom Kippur prayer), For Prof. Cohen is like a candle providing us a glimpse to new technologies".